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Abstract  
An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer 
inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) 
coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we 
demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to 
target the lungs following intravenous administration. In this study, we used emulsification 
and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying 
contents of the derivative A, in order to examine the selective toxicity towards 
cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading 
process, and the content of the poorly water soluble derivative A was estimated directly via 
the DSC technique. The particles were spherical in shape with the d50 distribution varying 
between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 
wt%. Cell-selective cytotoxicity was examined simultaneously on two cell lines: human lung 
carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). 
All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than 
towards healthy cells (MRC5), where the particles with the derivative A content of 6.5wt% 
allowed for the viability of healthy cells greater than 80%. Ninety-six hours after the 
treatment of cells with particles with different contents of derivative A (after incubation and 
recovery), recovery was faster in damaged healthy cells than in cancerous cells. 
 




Calcium phosphates, especially hydroxyapatite (HAp), as the most common inorganic bone 
component [1], have a high potential for use in preventive and regenerative medicine [2, 3]. 
The past decade has witnesses a significant growth of research into the application of HAp 
particles, not only as a material for the reconstruction of bone tissue but also as a drug carrier 
in biomedicine [4]. Hydroxyapatite nanoparticles (HApNs) have shown selective anti-cancer 
activity in the treatment of lung cancer. The cytotoxic activity of HApNs towards human lung 
cancer cells (A549) has been demonstrated to be significant, without affecting the survival of 
normal bronchial epithelial 16HBE cells [5]. The research aimed at creating new functional 
and hybrid systems based on HAp largely expands the potential for its application for 
biomedical purposes [6]. In our previous study, we examined the possibility of applying 
multifunctional and hybrid systems based on HAp and bioresorbable polymers in the 
reconstruction of bone tissue damaged by osteoporosis [7, 8]. 
Nano-carriers for cancer inhibitors are a promising strategy in increasing the treatment 
efficiency for various types of cancer, accompanied with an increased toxicity towards cancer 
cells and decreased toxicity towards healthy cells [9]. Lung cancer is one of the most common 
and the most lethal cancer types at a global level [10]. An analysis of the delivery efficiency 
of nanoparticles in different tumor types indicates that it is the lowest in cases of lung tumors. 
[11]. There are different strategies seeking not only to improve the delivery efficiency, but 
also to increase the drug content in the carrier. One of them is to design a synthetic system 
where the system/carrier molecules would firmly grip and entrap the drug. These cage 
nanoparticles could be promising vehicles for continuous drug delivery [12]. 
Biodegradable polymer particles based on poly-lactide-co-glycolide (PLGA) have 
been used as suitable vehicles for various cancer inhibitors targeting the lungs after 
intravenous application [13]. Core-shell particles based on PLGA and linear polysaccharide 
chitosan (Ch) loaded with cancer inhibitors have shown a high potential in the treatment of 
lung cancer [14, 15]. PLGA nanoparticles modified with Ch have also shown a high potential 
as nano-carriers of poorly hydrophilic drugs in the treatment of breast cancer [16]. Dual-drug 
containing core–shell nanoparticles based on PLGA and Ch were designed to reduce and 
eliminate toxicity to healthy human cells in potential lung cancer therapy and their efficiency 
was tested. Particles with the hydrodynamic diameter of 289±49 nm were cyto- and chemo-
compatible, and they operated by targeting folate receptors [17]. During in vivo studies, it was 
found that after the intravenous application of spherical nano-HAp-based particles coated with 
a polymeric PLGA-Ch blend, they were accumulated in the lungs [18, 19]. Spherical 
HAp/Ch-PLGA particles with hydrodynamic properties that allow to direct them towards the 
lungs following injection could play the role of vehicles in drug delivery for various lung 
diseases. Polymer components that coat nano-HAp particles could be optimal for the 
entrapment of various drugs. A wide variety of different androstane derivatives with a 
heterocyclic ring showed a high potential as cancer inhibitors in the treatment of hormone-
dependent cancers [20–22]. 
In our previous research, we examined the possibility of synthesizing and designing 
HAp/Ch-PLGA spherical particles loaded with17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-
acetate (A). The results of in vitro tests indicated selective A-HAp/Ch-PLGA activity; the 
particles did not exhibit cytotoxicity towards primary mouse lung fibroblasts (C57BL/6) but 
they were cytotoxic for lung cancer cells [23]. In the present study, we demonstrate the 
synthesis and design of spherical HAp/Ch-PLGA particles loaded with varying contents of an 
androstane-based cancer inhibitor (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate, A). 
The influence of the content of androstane derivative on the morphology and size distribution 
of the synthesized particles was also examined. The content of androstane derivatives in all 
systems was determined directly using the DSC technique. The electrokinetic parameters of 
all particles as potential activity indicator in the middle particle layer – biological 
environment were determined by measuring zeta potential, electrophoretic mobility and 
conductivity. The influence of the content of the androstane-based cancer inhibitor A on cell-
selective toxicity was examined simultaneously on two cell lines: on human lung carcinoma 
(A549) and human lung fibroblasts (MRC-5) using dye exclusion (DET) and MTT assays. 
The viability of both cell types after the treatment with synthesized particles was also 




2.1. Synthesis of materials 
2.1.1. Synthesis of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate (A)  
The first stage in the preparation of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (A) 
was the addition of α-picolyllithium to the 17-oxo group of dehydroepiandrosterone, resulting 
in 17α-picolyl-androst-5-en-3β,17β-diol. This was followed by acetylation using acetic 
anhydride in absolute pyridine at room temperature for 3 h [24, 25]. 
 
2.1.2. Synthesis of HAp, HAp/Ch-PLGA and A-loaded HAp/Ch-PLGA 
An aqueous calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6 wt.%) was added to the 
solution of ammonium phosphate ((NH4)3PO4) (7 ml H3PO4+165 ml NH4OH+228 ml H2O) at 
50°C over the period of 60 minutes, while stirring at the rate of 100 rpm. The solution was 
then subjected to a heat treatment at 100°C for 60 minutes. The resulting gel was dried at 
room temperature in a vacuum drier for 72 h, after which the final product – HAp powder - 
was obtained. X-ray diffraction run on the HAp powder confirmed its poorly crystalline 
nature, whereas the PSD technique enabled us to determine the particle size of d50=70 nm 
[26]. 
Chitosan (Ch) of a low molecular weight (Aldrich, deacetylation>75%), dissolved in 
acetic acid (1 wt.%), was mixed with 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate 
powder (A) in the weight ratio according to Table 1, while stirring with a magnetic stirrer at 
400 rpm. PLGA (50:50, Sigma, USA) dissolved in acetone was mixed with the A-containing 
Ch solution and HAp gel in the 2:3:5 weight ratio. A water solution of poloxamer 188 
(polyethylenepolypropylene glycol, 0.1 vol.%) was added drop-wise to the resulting mixture, 
while stirring at 21,000 rpm. The obtained mixture of A, chitosan, PLGA and HAp was 
slowly poured into a glutaraldehyde solution (Grade I, 25% in H2O), while stirring at 21,000 
rpm for 1 h. The obtained mixture was then centrifuged at 3000 rpm and 5°C for 1 h, and the 
resulting precipitate was subjected to lyophilization at temperatures ranging from -10 to -60°C 
and pressures ranging from 0.37 mbar to 0.1 mbar for 1 to 8h [23]. The obtained powder was 
washed with distilled water three times, centrifuged at 1000 rpm and dried again. The final 
product was the powder composed of HAp particles coated with A-loaded chitosan-
poly(D,L)-lactide-co-glycolide (Tab. 1).  
 
Table 1. The projected content of A in A-loaded HAp/Ch-PLGA 
 
2.2. Characterization of the products 
X-Ray diffraction (XRD) was performed on a Philips PW-1050 diffractometer with Ni-
filtered CuK  radiation, the scanning step was 0.02°. The particle size distribution (PSD) was 
measured on 10 mg/ml of powders dispersed in water using a Mastersizer 2000 (Malvern 
Instruments Ltd.) and a HydroS dispersion unit for liquid dispersants. Morphological 
characterization was performed using an atomic force microscope (AFM, Thermo 
Microscopes, Autoprobe CP Research). Content of HAp in the particles was determined by 
simultaneous TGDTA (Setsys 2400 CS Evolution, SETARAM Instrumentation, Caluire, 
France) in the temperature range between 30 and 600 C with the heating rate of 10 min
1 
and under the air flow of 20 mlmin
1
. Differential scanning calorimetry (DSC) measurements 
were performed on an Evo 131 (Setaram Instrumentation) differential scanning calorimeter. 
Samples were analyzed in nitrogen by heating (10°/min) from 25 to 360°C. Infrared 
spectroscopy (FT-IR) was done on a Nicolet iS10 FT-IR Spectrometer (Thermo Scientific 
Instruments) in the spectral range from 400 to 4000 cm
−1
. Electrokinetic parameters of the 
suspensions of synthesized particles were analyzed using a Zeta-Sizer Nano (Malvern 
Instruments Ltd.) in deionized water and pH 7.0. 
 
2.3 In vitro tests 
2.3.1 Cell lines 
Toxicity tests were carried out on two cell lines, human lung carcinoma (A549 ATCC CCL 
185) and human lung fibroblasts (MRC-5 ATCC CCL 171) which grew adhered to the dish 
floor (Costar, 25cm
3
) in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, UK) 
with 4.5 g/l glucose and 10% FCS (fetal calf serum, Sigma). The medium contained 
antibiotics: penicillin 100 IU/ml and streptomycin 100 μg/ml. The cell lines were maintained 
under standard conditions: at the temperature of 37°C in a humidity saturated atmosphere 
with 5% CO2 (Heraeus). The cells were passaged twice a week, and in the experiments the 
cells were used in the logarithmic growth phase between the third and tenth passages. Only 
viable cells were used. The number of cells and their viability were determined by a color 
rejection test with 0.1% trypan blue. 
 
2.3.2 DET - Dye exclusion test 
The cells were centrifuged (10 min/200xg) and counted in 0.1% trypan blue. Viable cells 
were sown in Petri cups (Center well, Falcon) containing the examined substance/disc at a 
concentration of 2×10
5
/ml. Control samples did not contain the test substance. Petri cups with 
seeded cells were left at 37°C, with 5% CO2 for 48 hours (h). After incubation, cell counting 
was performed using an inverted microscope (REICHERT) in counting chambers. 
Cytotoxicity was expressed as a percentage according to the formula: CI = (1-Ns/Nk)  100, 
where Nk is the number cells in the control samples, and Ns is the number of cells in the 
samples with the tested substance. 
 
2.3.3. Colorimetric test with tetrazolium salts (MTT test) 
The cells were harvested in the logarithmic growth stage, sedimented by centrifugation (10 
min/200 xg) and counted in 0.1% trypan blue. The viable cells were sown in Petri cups 
(Center well, Falcon) containing the tested substances/discs at a concentration of 2×10
5
/ml. 
The control samples did not contain the test substances. Petri cups with seeded cells were left 
in a thermostat at 37ºC, with 5% CO2 for 48 hours. Viable cells were seeded (5x10
3
 /100μl) in 
quadruplicate in 96-well microtiter plates. The plates with seeded cells were left in a 
thermostat at 37ºC, with 5% CO2 for 48 h. MTT solution, prepared immediately prior to 
addition, was added to all plate wells in the 10 μl/well volume and incubation was continued 
for 3h (in a 37°C thermostat with 5% CO2). After 3h, 100 μl of 0.04 mol /l HCl in isopropanol 
was added to each well. The absorbance was read immediately after the incubation period on 
the microtiter plate reader (Multiscan, MCC/340) at a wavelength of 540 nm and a reference 
of 690 nm. The wells on the plate that contained only the medium and MTT, but not the cells, 
served as blank [27]. Cytotoxicity was expressed as a percentage according to the formula: CI 
= (1-As/Ak)x100, whereby Ak is the absorbance of the control samples, and As is the 
absorbance of the samples with the test substance. 
 
3. Results and discussion  
 
Figure 1 shows the diffractograms of A, HAp/Ch-PLGA and A-loaded HAp/Ch-PLGA. The 
androstane derivative (A) is characterized by peaks at the positions 14.7°, 15.6°, 17.4° and 
18.8°. The most intense peaks were recorded at 31.8° (2 1 1), 32.2° (1 1 2), 32.9° (3 0 0), 
25.9° (0 0 2) and 49.5° (2 1 3) and they originated from poorly crystalline, non-stoichiometric 
HAp [18]. The HAp/Ch-PLGA diffractogram confirms the presence of HAp and Ch. Namely, 
in addition to characteristic HAp peaks, two reflections detected at 10.2° and 19.8° originated 
from Ch [28]. The absence of PLGA peaks on the diffractograms indicates that the polymer is 
amorphous, as confirmed in our earlier XRD studies. The presence of characteristic peaks of 
derivative A in diffractograms of A1, 2 and 3-HAp/Ch-PLGA powders qualitatively confirms the 
presence of A in A-HAp/Ch-PLGA. 
 
Figure 1. XRD of A, HAp/Ch-PLGA, A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-
HAp/Ch-PLGA 
 
The morphology and distribution of particle size of the synthesized powders A1,2 and 3-
HAp/Ch-PLGA is shown in Figure 2. A1-HAp/Ch-PLGA particles have d10 = 135 nm; d50=67 
nm and d90= 42 nm. The A2-HAp/Ch-PLGA system has the distribution  values d10 =135 nm, 
d50=168 nm and d90=247 nm, and A3-HAp/Ch-PLGA d10=162 nm, d50=231 nm and d90=453 
nm (Figure 2a-c). A general trend of increased average particle sizes (d50) with an increased 
content of the derivative A was observed. The surface morphology of A1, 2 and 3-HAp/Ch-
PLGA was analyzed using AFM in a non-contact mode. All three types of particles had 
similar spherical morphologies. 
 
Figure 2. PSD and AFM of particles: a) A1-HAp/Ch-PLG, b) A2-HAp/Ch-PLGA and c) A3-
HAp/Ch-PLGA 
 
Figure 3 shows the IR spectra of A, A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-
HAp/Ch-PLGA. The wide IR band in the spectrum of A (17β-hydroxy-17α-picolyl-androst-5-
ene-3β-yl acetate) with a maximum of about 3300 cm
-1
 was assigned to the stretching 
vibration of the OH group (17β-OH). Several absorption bands at about 2943 and 2827 cm
-1
 
came from the alkyl stretching vibrations of the -CH group (from -CH3 and =CH2). The valent 
vibrations of the acetate group were recorded as sharp bands with a maximum of about 1242 
cm
-1
, which is in line with the studies of other authors [29, 23]. The presence of the 
characteristic bands of pure derivative A was also established in the particle spectra of all 
three systems, which qualitatively confirms the presence of derivative A in the particles 
HAp/Ch-PLGA. In all spectra of the A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-
HAp/Ch-PLGA particles, the characteristic bands of HAp, Ch and PLGA were also observed. 
The characteristic bands at about 1030 cm
-1
 and 1080 cm
-1
 could be assigned to the vibration 
of the PO4
3- 
group of HAp and the band at 3552 cm 
-1
 to vibration of the OH- group. The 
absorption band at about 563 cm
-1
 was assigned to the bending mode of the PO4
3- 
group [30]. 
Other significant bands originated from PLGA and Ch: -C=O stretching vibrations at about 
1725 cm
-1
, weak sharp bands at around 1655 cm
-1
 and 1580 cm
-1
 were assigned to Amid I and 
II vibrations, etc. [31-33]. In accordance with the methodology of introducing derivative A 
into the initially dissolved polymer PLGA and Ch (section 2.1.2.), in addition to the XRD 
results (Figure 1), IR results also qualitatively confirmed the encapsulation of derivative A by 
the used polymers. 
 
Figure 3. ATR FTIR spectra of A, A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-
PLGA 
 
The amount of HAp in the particles was determined by a TG-DTA analysis. The results of the 
TG-DTA analyses of derivate A, Ch, PLGA, A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-
HAp/Ch-PLGA in the 30-600 °C temperature range are shown in Fig. 4. The TGA curves of 
A (Fig, 4a), Ch (Fig. 4b) and PLGA (Fig. 4c) show complete degradation at 600 °C (100% 
mass loss). These results suggest that the residue in the composites (Fig. 4.d,e,f) originate 
from HAp. The TGA curve for A1-HAp/Ch-PLGA shown in Fig. 4a reveals a 52±0.5 % 
weight loss at 600°C. The residue of 48±0.5% in weight is only due to HAp. Similar results 
were obtained for composites A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA (Fig. 4e,f). The 
TGA curves for A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA show a 53±0.5% % weight loss at 
600°C. The obtained results indicate that the residue of 47±0.5% % wt. contains HAp. As can 
be seen from Fig 4d,e,f, the DTA curves of A-loaded HAp/Ch-PLGA are dominated by peaks 
characteristic for the pure compounds A, Ch and PLGA. The sequence of broad exothermic 
peaks originating from the degradation of Ch and PLGA is observed in each of the examined 
systems. The degradation mechanism of Ch and PLGA involve a random chain scission at the 
beginning of decomposition and a specific chain scission at the end. The TGA curves for A1-
HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA show no mass loss when 
exposed to the temperature range in which the evaporation and degradation of A, Ch and 
PLGA occur. This observation is in agreement with the DTA curves. 
 
Figure 4. TGA/DTA of a) A1, b) Ch, c) PLGA, d) A1-HAp/Ch-PLGA, e) A2-HAp/Ch-PLGA 
and f) A3-HAp/Ch-PLGA 
 
Differential scanning calorimetry (DSC) has proved to be suitable for determining the 
content of poorly water-soluble drugs in various pharmaceutical products, based on the 
measurement of phase transition enthalpy [34]. Androstane derivative A belongs to the group 
of poorly water-soluble compounds and its DSC thermogram is shown in Figure 5. The 
endothermic phase transition dominates the DSC thermogram of derivative A with a sharp 






C). The same phase 
transition is also noticeable on the thermograms of the A1-HAp/Ch-PLGA, A2-HAp/Ch-
PLGA and A3-HAp/Ch-PLGA particles (Figure 5). The wide endothermic doublet (onset 
49.4°C, offset 131.5°C) originates from the PLGA and Ch transformation [35, 36]. The 
exothermic peak at higher temperatures (onset 293.1°C, offset 329.4°C) comes from the 
deacetylation of Ch. By integrating the endothermic peaks of the characteristic phase 
transition of pure (100%) and encapsulated derivative A, the obtained enthalpy values (ΔH) 
are shown in Table 2. Based on a comparison of the enthalpy values of pure and encapsulated 
derivative A, it can be argued that the content of the encapsulated derivative A in A1-
HAp/Ch-PLGA 6.5%, in A2-HAp/Ch-PLGA 9.2% and in A3-HAp/Ch-PLGA 19.3%. The 
presented results are the average values obtained on three identically prepared samples. 
 
Figure 5. DSC of A, A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA 
 
Tabele 2. Enthalpy and content of A according to the DSC results 
 
Electrokinetic parameters are important not only for particle–particle interactions, but 
also for interactions between particles and the biological environment [36]. The influence of 
the zeta potential (-10.28 to -29.65 mV) of HAp particles on cellular uptake in human 
monocyte-macrophage cells was examined. It was found that particles with less negative 
values of zeta potential achieved a greater uptake [38, 39]. The results of zeta potential 
measurements for the particles based on poorly crystalline HAp showed that the presence of 
polysaccharides on the particle surface greatly increased their efficacy as nanocarriers in 
controlled drug delivery [40]. Table 3 shows the values of the zeta potential, electrophoretic 
mobility and conductivity of A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA 
particles. In general, the particles that have zeta potential values between 0 and ±15mV are 
prone to flocculation and aggregation, while absolute ZP values greater than 15mV are typical 
of stable and aggregately resistant particles [41, 42]. The most prone to aggregation were A1-
HAp/Ch-PLGA particles, less so A2-HAp/Ch-PLGA, while A3-HAp/Ch-PLGA particles were 
the most stable. The ZP values also served as a tool in the study of comparative interactions of 
nanoparticles with healthy and breast cancer cells. A difference in surface charge was 
observed between healthy and cancerous breast cells (MCF10A and MCF7), as well as 
different interaction types and intensities between the same nanoparticles and 
healthy/cancerous cells [43]. Based on the results shown in Table 3, it was expected that all 
three types of the synthesized particles would exhibit a different activity towards 
healthy/cancerous cells, which was also investigated in subsequent in vitro studies. 
In addition to a small difference in the particle sizes d50 of all three systems (Figure 2), 
the basic difference is reflected in the fraction of the derivative A (Table 2). With an increased 
content of derivative A in the particles, a change was expected in the content of the surface 
groups and ions resulting from the dissociation of the derivatives. Changes in the ionic 
composition of the nanoparticle environment can result in the appearance of specific and non-
specific ion effects [44]. The reduction of the mobility value and an increased conductivity 
that accompanied the increased content of derivative A in the system were most likely the 
result of ion effects rather than the difference in particle sizes. 
 
Table 3. Zeta potential, electrophoretic mobility and conductivity of A1-HAp/Ch-PLGA, A2-
HAp/Ch-PLGA and A3-HAp/Ch-PLGA particles (ξ—zeta potential; ue—mobility; K-
conductivity). 
 
Figure 6 shows the results of the testing of the cytotoxicity and viability of healthy and 
cancerous lung cells (MRC5 and A549) after incubation with A, drug free HAp/Ch-PLGA, 
A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA performed using DET and 
MTT assays. The results of the comparative cytotoxicity tests of A1-HAp/Ch-PLGA, A2-
HAp/Ch-PLGA and A3-HAp/Ch-PLGA particles towards MRC5 and A549 cells are shown in 
Figure 6a. As the content of A increased in the HAp/Ch-PLGA carrier, the particles exhibited 
more intensive cytotoxicity towards both cell lines. Cytotoxic activity is significantly more 
pronounced towards lung cancer cells (A549) than to healthy cells (MRC5), almost three 
times for each type of particles with derivative A. The cell viability results were obtained after 
48 h of incubation with the particles of A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-
HAp/Ch-PLGA, washing and counting in 0.1% trypan blue (Fig. 6b). With an increased 
content of derivative A in the carrier, the achieved cellular viability decreased. Based on the 
results shown in Figure 6b, it is clear that the viability of healthy cells (MRC5) is always 
higher than that of malignant cells (A549) in all three investigated systems with different 
contents of derivative A. The viability of healthy cells (MRC5) was higher than 80% for the 
particles of A1-HAp/Ch-PLGA (82.12%), while for A2-HAp/Ch-PLGA and A3-HAp/Ch-
PLGA it was lower than 80% (69.67 and 62.12%). After an 48-hour incubation with particles 
of A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA, both cell lines (MRC5 
and A549) were left to recover for 48 h and the obtained cytotoxicity results are shown in 
Figure 6c. After the recovery, the cytotoxicity values were more pronounced in malignant 
cells (A549) than in healthy ones (MRC5), which demonstrates a more intensive recovery of 
healthy cells, compared to the malignant ones. The action mechanism of synthetic androstane 
derivatives on hormone-dependent cancer cells has not been fully elucidated. Previous in vitro 
and in vivo tests with androstane derivatives indicated their unique properties, such as tissue-
selective cytotoxicity, target specificity and implications for the treatment of inoperable 
malignancies [45]. 
 
Figure 6. In vitro test of A1-HAp/Ch-PLGA, A2-HAp/Ch-PLGA and A3-HAp/Ch-PLGA on 
two cell lines: regular MRC5 human lung fibroblasts and A549 human lung carcinoma cells: 
a) cytotoxicity and b) viability estimated using dye exclusion test (DET); c) cytotoxicity 
following a 48-hour recovery period estimated using the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. 
 
The path of energy modulation of cancer cells (A549) is different from that of healthy 
cells (MRC5). In previous research, it was established that, in contrast to normal cells, cancer 
cells may lose the ability to utilize aerobic respiration due to either defective mitochondria or 
hypoxia within tumor microenvironments [46]. The cytotoxicity results show that MRC5 cells 
are less sensitive than A549 cells, which are more susceptible to the action of A-loaded 




Spherical particles were created as suitable vehicles for varying contents of a poorly water 
soluble androstane derivative, 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (A), from 
nano-sized hydroxyapatite (HAp) coated with a polymer blend consisting of chitosan (Ch) 
poly-lactide-co-glycolide (PLGA). XRD and FT-IR analyses confirmed the efficiency of the 
drug loading process and the DSC technique determined the content of derivative A in the 
HAp/Ch-PLGA carriers, which was 6.5wt%, 9.2wt%, and 19.3wt%. As the content of 
derivative A increased, so did the median value of the particle size distribution – particles 
with 6.5wt% A had d50 167 nm, with 9.2wt% 168 nm and with 19.3wt% 231 nm. An 
increased content of derivative A in the carrier reduced the values of zeta potential and 
electrophoretic mobility and increased the conductivity of the particles, most likely due to 
changes in the ionic environment around the particles. The anti-cancer selectivity of the 
particles was confirmed on two cell lines: human lung carcinoma (A549) and human lung 
fibroblasts (MRC-5) using dye exclusion (DET) and MTT assays. All types of A-loaded 
HAp/Ch-PLGA showed almost three times larger cytotoxicity towards cancerous cells than to 
healthy ones. Forty-eight hours after the treatment of both types of cells with the particles of 
HAp/Ch-PLGA loaded with A (6.5wt.%) that had the lowest zeta potential (-9.61±0.37 mV), 
the viability of healthy cells was 82.12%. The particles with the lowest zeta potential (-
33.3±2.35 mV) for HAp/Ch-PLGA loaded with A (19.3 wt%) were the most cytotoxic to both 
cell lines (A549 and MRC-5). Ninety-six hours after the treatment of both types of cells with 
the particles of A-loaded HAp/Ch-PLGA, for all contents of derivative A, the recovery of 





The research presented in this paper was supported by the Ministry of Education, Science and 
Technological Development of the Republic of Serbia (project No. III45004). The authors 
acknowledge the help of Dr. Kata Trifković of the Faculty of Technology and Metallurgy, 
University of Belgrade, for the zeta potential measurements. The authors would also like to 
thank to Dr. Ljilijana Veselinović for XRD measurements and Dr. Dana Vasiljević-Radović 




[1] J.F. Osborn, H. Newesely, The material science of calcium phosphate ceramics, 
Biomaterials. 1 (1980) 108–111. doi:10.1016/0142-9612(80)90009-5. 
[2] W. Habraken, P. Habibovic, M. Epple, M. Bohner, Calcium phosphates in biomedical 
applications: Materials for the future?, Mater. Today. 19 (2016) 69–87. 
doi:10.1016/j.mattod.2015.10.008. 
[3] S. Bose, S. Tarafder, Calcium phosphate ceramic systems in growth factor and drug 
delivery for bone tissue engineering: A review, Acta Biomater. 8 (2012) 1401–1421. 
doi:10.1016/j.actbio.2011.11.017. 
[4] A. Haider, S. Haider, S.S. Han, I.-K. Kang, Recent advances in the synthesis, 
functionalization and biomedical applications of hydroxyapatite: a review, RSC Adv. 7 
(2017) 7442–7458. doi:10.1039/C6RA26124H. 
[5] Y. Sun, Y. Chen, X. Ma, Y. Yuan, C. Liu, J. Kohn, et al., Mitochondria-targeted 
hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and 
in vivo, ACS Appl. Mater. Interfaces. 8 (2016) 25680–25690. 
doi:10.1021/acsami.6b06094. 
[6] F. Ridi, I. Meazzini, B. Castroflorio, M. Bonini, D. Berti, P. Baglioni, Functional 
calcium phosphate composites in nanomedicine, Adv. Colloid Interface Sci. 244 (2017) 
281–295. doi:10.1016/j.cis.2016.03.006. 
[7] N.L. Ignjatović, P. Ninkov, R. Sabetrasekh, D.P. Uskoković, A novel nano drug 
delivery system based on tigecycline-loaded calciumphosphate coated with poly-DL-
lactide-co-glycolide, J. Mater. Sci. Mater. Med. 21 (2010) 231–239. 
doi:10.1007/s10856-009-3854-6. 
[8] N. Ignjatović, V. Uskoković, Z. Ajduković, D. Uskoković, Multifunctional 
hydroxyapatite and poly(d,l-lactide-co-glycolide) nanoparticles for the local delivery of 
cholecalciferol, Mater. Sci. Eng. C. 33 (2013) 943–950. 
doi:10.1016/j.msec.2012.11.026. 
[9] Z. Li, S. Tan, S. Li, Q. Shen, K. Wang, Cancer drug delivery in the nano era: An 
overview and perspectives (Review), Oncol. Rep. 38 (2017) 611–624. 
doi:10.3892/or.2017.5718. 
[10] E. Bender, Epidemiology: The dominant malignancy, Nature. 513 (2014) S2–S3. 
doi:10.1038/513S2a. 
[11] S. Wilhelm, A.J. Tavares, Q. Dai, S. Ohta, J. Audet, H.F. Dvorak, et al., Analysis of 
nanoparticle delivery to tumours, Nat. Rev. Mater. 1 (2016) 16014. 
doi:10.1038/natrevmats.2016.14. 
[12] S. Deshayes, R. Gref, Synthetic and bioinspired cage nanoparticles for drug delivery., 
Nanomedicine (Lond). 9 (2014) 1545–1564. doi:10.2217/nnm.14.67. 
[13] F. Ye, Å. Barrefelt, H. Asem, M. Abedi-Valugerdi, I. El-Serafi, M. Saghafian, et al., 
Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and 
anticancer drugs for drug delivery and imaging, Biomaterials. 35 (2014) 3885–3894. 
doi:10.1016/j.biomaterials.2014.01.041. 
[14] N. Arya, D.S. Katti, Poly(d,l-lactide-co-glycolide)-chitosan composite particles for the 
treatment of lung cancer, Int. J. Nanomedicine. 10 (2015) 2997–3011. 
doi:10.2147/IJN.S78120. 
[15] H.N. Ho, T.H. Tran, T.B. Tran, C.S. Yong, C.N. Nguyen, Optimization and 
characterization of artesunate-loaded chitosan-decorated poly(D,L-lactide-co-
glycolide) acid nanoparticles, J. Nanomater. 2015 (2015). doi:10.1155/2015/674175. 
[16] C.K. Thakur, N. Thotakura, R. Kumar, P. Kumar, B. Singh, D. Chitkara, et al., 
Chitosan-modified PLGA polymeric nanocarriers with better delivery potential for 
tamoxifen, Int. J. Biol. Macromol. 93 (2016) 381–389. 
doi:10.1016/j.ijbiomac.2016.08.080. 
[17] J.U. Menon, A. Kuriakose, R. Iyer, E. Hernandez, L. Gandee, S. Zhang, et al., Dual-
drug containing core-shell nanoparticles for lung cancer therapy, Sci. Rep. 7 (2017) 
13249. doi:10.1038/s41598-017-13320-4. 
[18] N. Ignjatović, S. Vranješ Djurić, Ž. Mitić, D. Janković, D. Uskoković, Investigating an 
organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ 
method of radioactive 125Iodine labeling, Mater. Sci. Eng. C. 43 (2014) 439–446. 
doi:10.1016/j.msec.2014.07.046. 
[19] S. Vranješ Đurić, N.L. Ignjatović, Radiolabeled functional nanoparticles in preventve 
and regenerative medicine, in: V. Uskoković, D. Uskoković (Eds.), Nanotechnologies 
Prev. Regen. Med., 1st ed., Elsevier, 2018: pp. 1–92. https://doi.org/10.1016/B978-0-
323-48063-5.00001-0. 
[20] J.J. Ajduković, K.M. Penov Gaši, D.S. Jakimov, O.R. Klisurić, S.S. Jovanović-Šanta, 
M.N. Sakač, et al., Synthesis, structural analysis and antitumor activity of novel 17α-
picolyl and 17(E)-picolinylidene A-modified androstane derivatives, Bioorganic Med. 
Chem. 23 (2015) 1557–1568. doi:10.1016/j.bmc.2015.02.001. 
[21] I. Kuzminac, O.R. Klisurić, D. Škorić, D. Jakimov, M. Sakač, Structural analysis and 
antitumor potential of novel 5,6-disubstituted-17a-homo-17-oxa-androstane 
derivatives, Struct. Chem. 28 (2017) 567–576. doi:10.1007/s11224-016-0815-9. 
[22] S. Bjedov, D. Jakimov, A. Pilipović, M. Poša, M. Sakač, Antitumor activity of newly 
synthesized oxo and ethylidene derivatives of bile acids and their amides and 
oxazolines, Steroids. 120 (2017) 19–25. doi:10.1016/j.steroids.2017.01.008. 
[23] N.L. Ignjatović, K.M. Penov-Gaši, V.M. Wu, J.J. Ajduković, V. V. Kojić, D. 
Vasiljević-Radović, et al., Selective anticancer activity of hydroxyapatite/chitosan-
poly(D,L)-lactide-co-glycolide particles loaded with an androstane-based cancer 
inhibitor, Colloids Surfaces B Biointerfaces. 148 (2016) 629–639. 
doi:10.1016/j.colsurfb.2016.09.041. 
[24] K.M. Penov Gaši, S.M. Stanković, J.J. Csanádi, E.A. Djurendić, M.N. Sakač, L. Medić 
Mijačević, et al., New D-modified androstane derivatives as aromatase inhibitors, 
Steroids. 66 (2001) 645–653. doi:10.1016/S0039-128X(01)00096-4. 
[25] K.M.P. Gaši, M.D.D. Brenesel, E.A. Djurendić, M.N. Sakač, J.J. Čanadi, J.J. Daljev, et 
al., Synthesis and biological evaluation of some 17-picolyl and 17-picolinylidene 
androst-5-ene derivatives, Steroids. 72 (2007) 31–40. 
doi:10.1016/j.steroids.2006.10.002. 
[26] N.L. Ignjatović, C.Z. Liu, J.T. Czernuszka, D.P. Uskoković, Micro- and nano-
injectable composite biomaterials containing calcium phosphate coated with poly(dl-
lactide-co-glycolide), Acta Biomater. 3 (2007) 927–935. 
doi:10.1016/j.actbio.2007.04.001. 
[27] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays, J. Immunol. Methods. 65 (1983) 55–63. 
doi:10.1016/0022-1759(83)90303-4. 
[28] N. Ignjatović, V. Wu, Z. Ajduković, T. Mihajilov-Krstev, V. Uskoković, D. 
Uskoković, Chitosan-PLGA polymer blends as coatings for hydroxyapatite 
nanoparticles and their effect on antimicrobial properties, osteoconductivity and 
regeneration of osseous tissues, Mater. Sci. Eng. C. 60 (2016) 357–364. 
doi:10.1016/j.msec.2015.11.061. 
[29] G.B. Djigoué, B.T. Ngatcha, J. Roy, D. Poirier, Synthesis of 5α-Androstane-17-spiro-
δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as 
inhibitors of 17β-hydroxysteroid dehydrogenases, Molecules. 18 (2013) 914–933. 
doi:10.3390/molecules18010914. 
[30] A. Lak, M. Mazloumi, M.S. Mohajerani, S. Zanganeh, M.R. Shayegh, A. Kajbafvala, 
et al., Rapid formation of mono-dispersed hydroxyapatite nanorods with narrow-size 
distribution via microwave irradiation, J. Am. Ceram. Soc. 91 (2008) 3580–3584. 
doi:10.1111/j.1551-2916.2008.02690.x. 
[31] S.N. Tammam, H.M.E. Azzazy, H.G. Breitinger, A. Lamprecht, Chitosan nanoparticles 
for nuclear targeting: the effect of nanoparticle size and nuclear localization sequence 
density, Mol. Pharm. 12 (2015) 4277–4289. doi:10.1021/acs.molpharmaceut.5b00478. 
[32] Y. Shi, J. xue, L. Jia, Q. Du, J. Niu, D. Zhang, Surface-modified PLGA nanoparticles 
with chitosan for oral delivery of tolbutamide, Colloids Surfaces B Biointerfaces. 161 
(2018) 67–72. doi:10.1016/j.colsurfb.2017.10.037. 
[33] C.K. Thakur, N. Thotakura, R. Kumar, P. Kumar, B. Singh, D. Chitkara, et al., 
Chitosan-modified PLGA polymeric nanocarriers with better delivery potential for 
tamoxifen, Int. J. Biol. Macromol. 93 (2016) 381–389. 
doi:10.1016/j.ijbiomac.2016.08.080 
[34] L.C. Alskär, C.J.H. Porter, C.A.S. Bergström, Tools for early prediction of drug 
loading in lipid-based formulations, Mol. Pharm. 13 (2016) 251–261. 
doi:10.1021/acs.molpharmaceut.5b00704. 
[35] X. Qu, A. Wirsén, A.C. Albertsson, Effect of lactic/glycolic acid side chains on the 
thermal degradation kinetics of chitosan derivatives, Polymer (Guildf). 41 (2000) 
4841–4847. doi:10.1016/S0032-3861(99)00704-1. 
[36] A.T.C.R. Silva, B.C.O. Cardoso, M.E.S.R. e Silva, R.F.S. Freitas, R.G. Sousa, 
Synthesis, characterization, and study of PLGA copolymer in vitro degradation, J. 
Biomater. Nanobiotechnol. 6 (2015) 8–19. doi:10.4236/jbnb.2015.61002. 
[37] A.E. Nel, L. Mädler, D. Velegol, T. Xia, E.M. V. Hoek, P. Somasundaran, et al., 
Understanding biophysicochemical interactions at the nano–bio interface, Nat. Mater. 8 
(2009) 543–557. doi:10.1038/nmat2442. 
[38] M. Motskin, D.M. Wright, K. Muller, N. Kyle, T.G. Gard, A.E. Porter, et al., 
Hydroxyapatite nano and microparticles: Correlation of particle properties with 
cytotoxicity and biostability, Biomaterials. 30 (2009) 3307–3317. 
doi:10.1016/j.biomaterials.2009.02.044. 
[39] L. Chen, J.M. Mccrate, J.C.-M. Lee, H. Li, The role of surface charge on the uptake 
and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells, 
Nanotechnology. 22 (2011) 105708. doi:10.1088/0957-4484/22/10/105708. 
[40] S. Yamane, A. Sugawara, Y. Sasaki, K. Akiyoshi, Nanogel-calcium phosphate hybrid 
nanoparticles with negative or positive charges for potential biomedical applications, 
Bull. Chem. Soc. Jpn. 82 (2009) 416–418. doi:10.1246/bcsj.82.416. 
[41] R. Xu, Progress in nanoparticles characterization: Sizing and zeta potential 
measurement, Particuology. 6 (2008) 112–115. doi:10.1016/j.partic.2007.12.002. 
[42] V. Uskoković, Dynamic light scattering based microelectrophoresis: main prospects 
and limitations, J. Dispers. Sci. Technol. 33 (2012) 1762–1786. 
doi:10.1080/01932691.2011.625523. 
[43] Y. Zhang, M. Yang, N.G. Portney, D. Cui, G. Budak, E. Ozbay, et al., Zeta potential: A 
surface electrical characteristic to probe the interaction of nanoparticles with normal 
and cancer human breast epithelial cells, Biomed. Microdevices. 10 (2008) 321–328. 
doi:10.1007/s10544-007-9139-2. 
[44] C. Pfeiffer, C. Rehbock, D. Huhn, C. Carrillo-Carrion, D.J. de Aberasturi, V. Merk, et 
al., Interaction of colloidal nanoparticles with their local environment: the (ionic) 
nanoenvironment around nanoparticles is different from bulk and determines the 
physico-chemical properties of the nanoparticles, J. R. Soc. Interface. 11 (2014) 
20130931. doi:10.1098/rsif.2013.0931. 
[45] R. Bansal, P.C. Acharya, Man-made cytotoxic steroids: Exemplary agents for cancer 
therapy, Chem. Rev. 114 (2014) 6986–7005. doi:10.1021/cr4002935. 
[46] I.O. Farah, Differential modulation of intracellular energetics in A549 and MRC-5 cells, 




































Name Enthalpy, ΔH of encapsulated A 
[J/g] 
The content of the encapsulated A 
[%] 
A, pure 81.4 100 
A1-HAp/Ch-PLGA 5.3 6.5 
A2-HAp/Ch-PLGA 7.5 9.2 













A1-HAp/Ch-PLGA 25 -9.6±0.4 -0.75±0.03 13.9±0.73 
A2-HAp/Ch-PLGA 25 -19.2±1.0 -1.51±0.08 21.5±1.9 
A3-HAp/Ch-PLGA 25 -33.3±2.4 -2.61±0.18 27.2±3.2 
 
